Esperion Therapeutics (ESPR) Amortization of Deferred Charges (2012 - 2026)
Esperion Therapeutics (ESPR) posted Amortization of Deferred Charges of $589000.0 for Q1 2026, down 8.11% on a QoQ basis from $641000.0 in Q4 2025, and down 15.74% year-over-year from $699000.0 in Q1 2025.
Esperion Therapeutics (ESPR) Amortization of Deferred Charges (2012 - 2026) Analysis & Trends
Esperion Therapeutics' Amortization of Deferred Charges history runs 13 years deep, the most recent figure standing at $589000.0 for Q1 2026.
- Quarterly Amortization of Deferred Charges fell 15.74% year-over-year to $589000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (down 13.61% YoY) and the FY2025 annual result came in at $3.0 million, up 100.73% from the prior year.
- Amortization of Deferred Charges was $589000.0 for Q1 2026 at Esperion Therapeutics, down from $641000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $699000.0 in Q1 2025 and bottomed at $100000.0 in Q3 2025.
- A 5-year average of $415058.8 and a median of $417000.0 in 2023 frame the typical range for Amortization of Deferred Charges.
- Peak annual rise in Amortization of Deferred Charges reached 272.67% in 2025, while the deepest fall reached 75.0% in 2025.
- Esperion Therapeutics' Amortization of Deferred Charges stood at $414000.0 in 2022, then rose by 4.11% to $431000.0 in 2023, then sank by 60.09% to $172000.0 in 2024, then soared by 272.67% to $641000.0 in 2025, then declined by 8.11% to $589000.0 in 2026.
- Business Quant data shows ESPR's Amortization of Deferred Charges at $589000.0 in Q1 2026, $641000.0 in Q4 2025, and $100000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.58 Bn | 86.72 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.90 Bn | 32.16 Bn | 1.97 Bn |
| 3 | Zoetis | 32.33 Bn | 30.39 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.49 Bn | 23.43 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.14 Bn | 20.99 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - |
| 7 | Viatris | 20.29 Bn | 18.49 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.93 Bn | 16.62 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.63 Bn | 12.21 Bn | 785.00 Mn |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 589,000.00 |
| Mar 31, 2026 | 589,000.00 |
| Dec 31, 2025 | 641,000.00 |
| Dec 31, 2025 | 641,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Mar 31, 2025 | 699,000.00 |
| Mar 31, 2025 | 699,000.00 |
| Dec 31, 2024 | 172,000.00 |
| Dec 31, 2024 | 172,000.00 |
| Sep 30, 2024 | 400,000.00 |
| Sep 30, 2024 | 400,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Mar 31, 2024 | 437,000.00 |
| Mar 31, 2024 | 437,000.00 |
| Dec 31, 2023 | 431,000.00 |
| Dec 31, 2023 | 431,000.00 |